Agios Announces New Commercial Leadership Structure
April 02 2019 - 4:00PM
Darrin Miles Appointed Senior Vice President,
U.S. Commercial & Global Marketing; Previously Served as Vice
President, Oncology Program Leadership at Agios
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of
cellular metabolism to treat cancer and rare genetic diseases,
today announced two newly created commercial leadership roles to
support the commercialization of the company’s medicines in the
United States and Europe. Darrin Miles, who has been with the
company since 2015, most recently as vice president, oncology
program leadership, has been promoted to senior vice president,
U.S. commercial and global marketing and will be responsible for
leading the commercial organization in the U.S. and driving
coordinated marketing efforts worldwide for all of Agios products
and development candidates. In addition, a search is underway for
the role of senior vice president, international, who will be
responsible for building and leading the company’s operations
outside of the U.S. in support of the potential launch of TIBSOVO®
in Europe and potentially other select markets. Both will report to
Jackie Fouse, Ph.D., chief executive officer at Agios.
“It's an incredibly exciting time for Agios as
we continue to execute on the U.S. launch of our first wholly owned
medicine and prepare for our first approval in the EU. We believe
this new leadership structure will provide the greatest possible
expertise and focus for our team across both geographies,” said Dr.
Fouse. “Darrin has been instrumental in the strategy and success of
the IDH franchise to date, and we are confident that his new role,
working closely with the newly established international role, will
maximize the full value potential of TIBSOVO® for patients
worldwide and position us well for future expected launches across
our oncology and rare genetic disease programs.”
Mr. Miles has more than 20 years of experience
across a range of commercial and program management roles in
pharmaceuticals and biotechnology. He joined Agios in 2015 as vice
president, oncology marketing and market analytics and most
recently served as vice president, oncology program leadership,
where he has been instrumental in setting the strategy for the IDH
portfolio and leading the program team through the development and
approval of TIBSOVO®. Prior to joining Agios, Mr. Miles spent 14
years at Genentech, where he held roles of increasing
responsibility including marketing, sales management, reimbursement
and lifecycle leadership supporting a broad portfolio of brands
including Rituxan®, Herceptin®, Tarceva® and Lucentis®. He also led
the U.S. launches of next generation anti-HER2 treatments Perjeta®
and Kadcyla®. Prior to Genentech, Mr. Miles spent a number of years
at ALZA Corporation and SmithKline Beecham (now GSK) in numerous
roles including marketing, market analytics and organization
development. Mr. Miles holds a B.S. in applied economics with a
minor in biological sciences from Cornell University.
About AgiosAgios is focused on
discovering and developing novel investigational medicines to treat
cancer and rare genetic diseases through scientific leadership in
the field of cellular metabolism. In addition to an active research
and discovery pipeline across both therapeutic areas, Agios has two
approved oncology precision medicines and multiple first-in-class
investigational therapies in clinical and/or preclinical
development. All Agios programs focus on genetically identified
patient populations, leveraging our knowledge of metabolism,
biology and genomics. For more information, please visit the
company's website at www.agios.com.
Cautionary Note Regarding
Forward-Looking StatementsThis press release contains
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements include those regarding the expected benefits of Mr.
Miles’s employment and Agios’ strategic plans and focus. The words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," "outlook" and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from Agios' current expectations and beliefs. For
example, there can be no guarantee that any product candidate Agios
is developing will successfully commence or complete necessary
preclinical and clinical development phases, that development of
any of Agios' product candidates will successfully continue, or
that any positive developments in Agios' business will result in
stock price appreciation. Management's expectations and, therefore,
any forward-looking statements in this press release could also be
affected by risks and uncertainties relating to a number of other
important factors, including: Agios' results of clinical trials and
preclinical studies, including subsequent analysis of existing data
and new data received from ongoing and future studies; the content
and timing of decisions made by the U.S. FDA and other
regulatory authorities, investigational review boards at clinical
trial sites and publication review bodies; Agios' ability to obtain
and maintain requisite regulatory approvals and to enroll patients
in its planned clinical trials; unplanned cash requirements and
expenditures; competitive factors; Agios' ability to obtain,
maintain and enforce patent and other intellectual property
protection for any product candidates it is developing; Agios'
ability to maintain key collaborations; and general economic and
market conditions. These and other risks are described in greater
detail under the caption "Risk Factors" included in Agios’ public
filings with the Securities and Exchange Commission. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Agios expressly disclaims any
obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
Investor & Media
ContactHolly Manning, 617-844-6630Associate Director,
Investor RelationsHolly.Manning@agios.com
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Apr 2023 to Apr 2024